Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01936480 · ClinicalTrials.gov registry record · Phase 4
Genetics of QT Response to Moxifloxacin
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT01936480: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01936480 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 51 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01936480, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in healthy subjects using moxifloxacin.
Primary Outcome
We will measure the QT interval on ECG up to 6 hours after administration of moxifloxacin or placebo
Interventions
- DRUG Moxifloxacin 400mg once time
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2013-10 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 4 |
Why NCT01936480 stopped before completion
NCT01936480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which Moxifloxacin 400mg once time is the first listed.
NCT01936480 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01936480 about?
NCT01936480 is a clinical study titled "Genetics of QT Response to Moxifloxacin". The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in healthy subjects using moxifloxacin.
What is the current status of trial NCT01936480?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2013-10. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT01936480?
The interventions under investigation include: Moxifloxacin 400mg once time (DRUG).
Who is sponsoring clinical trial NCT01936480?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01936480's enrollment target sits among peer trials
51 1249th of 2000 higher than 746 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia